Latest Insider Transactions at Revance Therapeutics, Inc. (RVNC)
This section provides a real-time view of insider transactions for Revance Therapeutics, Inc. (RVNC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Revance Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Revance Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2021
|
Aubrey Rankin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,905
+12.99%
|
-
|
|
Feb 01
2021
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-6.94%
|
$827,975
$25.95 P/Share
|
|
Dec 31
2020
|
Dustin S Sjuts President |
BUY
Other acquisition or disposition
|
Direct |
348
+0.76%
|
$7,308
$21.36 P/Share
|
|
Dec 31
2020
|
Tobin Schilke CFO |
BUY
Other acquisition or disposition
|
Direct |
493
+1.0%
|
$10,353
$21.36 P/Share
|
|
Dec 30
2020
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-6.49%
|
$894,213
$27.82 P/Share
|
|
Dec 15
2020
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
562
-1.23%
|
$14,612
$26.75 P/Share
|
|
Dec 15
2020
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,556
-3.12%
|
$40,456
$26.75 P/Share
|
|
Nov 30
2020
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-6.09%
|
$761,737
$23.85 P/Share
|
|
Oct 29
2020
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-5.74%
|
$861,094
$26.15 P/Share
|
|
Oct 13
2020
|
Mark J Foley CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
66,106
-7.91%
|
$1,784,862
$27.62 P/Share
|
|
Sep 30
2020
|
Dwight Moxie CLO & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
4,236
-11.37%
|
$105,900
$25.14 P/Share
|
|
Sep 30
2020
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
12,250
+24.75%
|
-
|
|
Sep 30
2020
|
Abhay Joshi COO, President of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
7,382
-6.19%
|
$184,550
$25.14 P/Share
|
|
Sep 30
2020
|
Abhay Joshi COO, President of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+12.79%
|
-
|
|
Sep 30
2020
|
Tobin Schilke CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,446
-9.85%
|
$136,150
$25.14 P/Share
|
|
Sep 30
2020
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,750
+22.17%
|
-
|
|
Sep 30
2020
|
Mark J Foley CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
143,269
-20.05%
|
$3,581,725
$25.14 P/Share
|
|
Sep 30
2020
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Direct |
301,000
+29.64%
|
-
|
|
Sep 30
2020
|
Dustin S Sjuts President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,051
-11.73%
|
$151,275
$25.14 P/Share
|
|
Sep 30
2020
|
Dustin S Sjuts President |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+25.34%
|
-
|
|
Sep 28
2020
|
Aubrey Rankin Director |
SELL
Open market or private sale
|
Indirect |
33,119
-5.43%
|
$861,094
$26.18 P/Share
|
|
Jul 23
2020
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
50,913
+41.79%
|
-
|
|
Jul 23
2020
|
Mark J Foley CEO |
BUY
Grant, award, or other acquisition
|
Direct |
264,439
+24.04%
|
-
|